Report any antibiotic side effects that develop during tirzepatide therapy, such as nausea, vomiting, diarrhea, or abdominal paintirzepatide can amplify gastrointestinal symptoms
This research was supported by grants from the NIH (DK074970), the American Diabetes Association (7-13-BS-101) and the Price-Goldsmith Endowed Chair at Tulane University
Since each tissue type exhibits unique traits such as vascularization, immune profile, and biomechanical properties, tailored approaches are essential for optimal treatment
As we have documented the tolerability of L-PAM+BSO when supported by autologous stem cell infusion in heavily pretreated relapsed and/or refractory neuroblastoma patients (NANT phase I study, NCT00005835, www.clinicaltrials.gov), using myeloablative L-PAM+BSO is clinically feasible